FEB 1·SouthCoastToday.com▲
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Therapies Inc. (NYSE American: OSTX) announced that its wholly-owned subsidiary, OS Animal Health Corp (OSAH), has filed a Form S-1 with the SEC for an Initial Public Offering, targeting a listing on NYSE American or Nasdaq Capital Markets in the first half of 2026. OS Therapies shareholders are expected to receive one share of OSAH for every ten shares of OS Therapies owned. OSAH will focus on re-establishing and commercializing OST-HER2 for canine osteosarcoma and other HER2-positive cancers, a treatment that has shown improved patient outcomes in canine studies.
JAN 12·FinancialContent▲
OS Therapies Enters into Warrant Inducement Agreements
OS Therapies announced it raised $7.53 million in gross proceeds from pre-existing investors through warrant exercise inducement and exchange offers. This capital provides runway into 2027 and will fund regulatory approval submissions for OST-HER2, commercial preparation activities, and preparations for an OS Animal Health spinoff. The company aims for regulatory approval of OST-HER2 in the US, UK, and EU in 2026 and plans to file a Biologics Licensing Application with the U.S. FDA by January 2026.
